Effective against influenza and COVID is also the ideal drug to prescribe to patients at the onset of any flu symptoms. QIFENDA is an oral anti-viral ideal for out-patient use, allowing patients to be treated at home, and reducing the burden on health care systems. QIFENDA is a highly effective oral antiviral administered at home, early in the course of infection, preventing transmission of the virus and hospitalization, ultimately saving lives. QIFENDA is uniquely positioned to address the current COVID-19 pandemic and future viral outbreaks now and into the future.
QIFENDA 400mg (Favipiravir) is a selective inhibitor of viral RNA-dependent RNA polymerase (RdRP) with potent antiviral activity against single-stranded RNA viruses, including coronaviruses. This is the protein responsible for “building” the viral proteins. QIFENDA can target the protein necessary for the coronavirus to replicate, creating mutations that make it impossible for the virus to copy itself.
Qifenda (Favipiravir) has the most extensive safety profile among all the COVID-19 treatments. Unlike other novel treatments, Favipiravir has been in the market for more than ten years. We have clinical trials safety data for more than 120000 patients in more than 98 clinical trials. Additionally, we have treated more than 1.7M COVID-19 patients directly, with no adverse effects or adverse events. Even at very high dosages, Favipiravir maintains an impeccable safety record.
Numerous Clinical studies (both randomize, post-marketing and observational) have shown that Favipiravir effectively shortens the time to recovery (from 1 to 3 days) and, more importantly, reduces the progression and hospitalization of the patients. When taken early, hence the importance of the availability and cost, Favipiravir is highly effective in reducing viral replication, therefore the severe short and long-term consequences of the COVID-19 infection.